There were 476 press releases posted in the last 24 hours and 447,134 in the last 365 days.

CEMP SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Shareholders of a Class Action Involving Cempra, Inc. and a Lead Plaintiff Deadline of January 3, 2017

NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Middle District of North Carolina on behalf of investors who purchased Cempra, Inc. (NASDAQ:CEMP) securities between May 1, 2016 and November 1, 2016.

Click here to learn about the case: There is no cost or obligation to you.

According to the complaint, during the Class Period, Cempra made false and/or misleading statements and/or failed to disclose that: (i) Cempra’s lead product candidate solithromycin posed significant safety risks for hepatotoxicity; and (ii) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times.

On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review of solithromycin, highlighting a significant safety signal for hepatotoxicity. Upon this news, shares of Cempra fell over 60% during intraday trading.

If you suffered a loss in Cempra you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email, by telephone at 212.425.1140, or visit

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880

Primary Logo